Primary Membranous Nephropathy Diagnostic Cascade, Serum
Use
The Primary Membranous Nephropathy Diagnostic Cascade is significant in distinguishing primary from secondary membranous nephropathy using an algorithmic approach. It monitors patients with membranous nephropathy who have very low antibody titers and screens for anti-phospholipase A2 receptor antibodies, which are highly specific for diagnosing primary membranous nephropathy. Approximately 70% to 75% of patients with primary membranous nephropathy test positive for anti-PLA2R antibodies. Changes in antibody titer often precede shifts in clinical status, offering predictive insights into clinical remission, relapse, or transplantation-related risks.
Special Instructions
Not provided.
Limitations
Absence of circulating anti-phospholipase A2 receptor autoantibodies does not rule out a diagnosis of primary membranous nephropathy. Diagnosis should not be based on a single test result. Clinical symptoms, physical examination results, and other laboratory tests are essential to achieve accurate diagnosis. Interfering substances, improper specimen collection, and handling may also affect test outcomes.
New York Approved
Methodology
Immunoassay (ELISA)
Biomarkers
LOINC Codes
- 73737-9 - PLA2R IgG Ser IA-aCnc
- 73737-9 - PLA2R IgG Ser IA-aCnc
Result Turnaround Time
3-7 days
Related Documents
For more information, please review the documents below
Specimen
Serum
Volume
1 mL
Minimum Volume
1 mL
Container
Plastic vial
Collection Instructions
Centrifuge and aliquot serum into a plastic vial. Preferred collection container is a Serum gel; red top is acceptable.
Causes for Rejection
Gross hemolysis
Stability Requirements
| Temperature | Period |
|---|---|
| Room Temperature | 8 hours |
| Refrigerated | 14 days |
| Frozen | 14 days |